Better Life Pharma has obtained its first set of data on its lead compound TD-0148A, a second-generation LSD derivative, with further preclinical studies underway to determine...
Delix Therapeutics has raised $70m in a Series A funding round which is expected to fund its drug discovery platform of novel neuroplasticity-promoting compounds known as...
Heroic Hearts UK research director Grace Blest-Hopley discusses the organisation’s groundbreaking study that will investigate the use of psilocybin for treating brain trauma in veterans.
Heroic Hearts UK CEO Keith Abraham discusses his journey to setting up the organisation which aims to help veterans living with PTSD.
Mind Medicine has presented its novel findings on LSD and psilocybin from several ongoing studies.
Mind Cure Health has joined the Digital Therapeutics Alliance in a bid to drive awareness and adoption of digital therapies.
As the ecosystem around psychedelics in Europe develops, UK-based Clerkenwell Health is cementing itself as a serious player on the continent with the appointment of clinical...
A new, pooled analysis has found that single-dose, clinical administration of LSD is safe in regards to acute psychological and physical harm in healthy subjects.
The first patient has received a dose of psilocybin in the world’s first trial investigating psilocybin as a treatment for a rare and debilitating headache disorder...
Origin Therapeutics is poising for public listing on the Canadian Securities Exchange (CSE).